had a reaction with Dupixent and the second COVID vaccine / headaches; This is a spontaneous report received from a Consumer or other non HCP from License Party. An adult female patient (unknown if pregnant) received BNT162b2 (BNT162B2 NOS), as dose 2, single (Lot number: 4F483A, Expiration Date: 31Aug2026) for covid-19 immunisation; dupilumab (DUPIXENT), as 300 mg qow (every other week; strength: 3000mg/2ml)) subcutaneous for dermatitis atopic. The patient’s relevant medical history included: “Arthritis” (ongoing); “Osteoporosis” (ongoing); “D.farinae mite extract” (unspecified if ongoing); “illness” (unspecified if ongoing). Concomitant medication(s) included: PROLIA; METHOTREXATE; ATORVASTATIN CALCIUM; PAXLOVID taken for covid-19 treatment; ALBUTEROL SULFATE HFA; KETOCONAZOLE; INCRUSE ELLIPTA; METOPROLOL SUCCINATE; METHYLPREDNISOLONE. Past drug history included: Bupropion hcl, reaction(s): “Drug allergies: Bupropion”; Wellbutrin sr, reaction(s): “allergic to Wellbutrin SR”. Vaccination history included: Covid-19 vaccine (dose 1; unknown manufacturer), for covid-19 immunization. The following information was reported: HEADACHE (hospitalization), outcome “unknown”, described as “had a reaction with Dupixent and the second COVID vaccine / headaches”. The action taken for dupilumab was unknown. Clinical course: On an unknown date, the patient started taking dupilumab solution for injection at a dose of 300 mg QOW (every other week) subcutaneously with strength of 3000mg/2ml delivered via prefilled pen for dermatitis atopic. On an unknown date, the patient received a dose of suspect COVID-19 VACCINE not produced by Sanofi Pasteur. Reportedly, patient had a reaction with DUPIXENT and the second covid vaccine that put her in the hospital (adverse drug reaction; onset and latency: unknown). She had an injection of methylprednisone yesterday and she was aware that there’s drug interactions between that and the Prolia. She was also prescribed methotrexate and it’s concerned about drug interaction as well. Patient Prolia therapy stated she did not want to take anymore. Stated she was not fully informed by her doctor of the side effects of the Prolia also concerned with drug interactions she has read online about. Stated the Prolia caused joint pain, and she already had arthritis. Also believed there is a contraindication to using Prolia with a methylprednisone injection she received last week and her methotrexate. Upon follow-up, patient reported arthritis and headaches (headache; onset date and latency: unknown) (batch number: 4F483A and expiry date on 31Aug2026) no additional details. SUSPECT PRODUCT is under agreement with BIONTECH SE.